VGX-3100 is a therapeutic vaccine for cervical dysplasia and cancer.
The grant will also support Inovio Pharma’s development projects for Syncon universal flu and dengue vaccines.
The PPACA provides small and mid-sized biotech, pharmaceutical and medical device companies with up to a 50% tax credit for investments in qualified therapeutic discoveries for tax years 2009 and 2010, or a grant for the same amount tax-free.